Analysts expect Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN – Get a rating) will post sales of $187.39 million for the current quarter, according to Zacks. Six analysts provided earnings estimates for Biohaven Pharmaceutical, with the lowest sales estimate of $171.03 million and the highest estimate of $200.00 million. Biohaven Pharmaceutical reported sales of $43.82 million in the same quarter last year, suggesting a positive year-over-year growth rate of 327.6%. The company is expected to release its next quarterly results on Monday, January 1.
According to Zacks, analysts expect Biohaven Pharmaceutical to report revenue of $934.20 million for the current fiscal year, with estimates ranging from $884.00 to $965.29 million. For next year, analysts expect the company to post sales of $1.38 billion, with estimates ranging from $1.22 billion to $1.46 billion. Zacks Investment Research’s sales calculations are an average average based on a survey of sell-side analysts who track Biohaven Pharmaceutical.
Biohaven Pharmaceutical (NYSE: BHVN – Get a rating) last announced its results on Thursday, February 24. The company reported ($3.01) earnings per share (EPS) for the quarter, missing analyst consensus estimates of ($2.04) by ($0.97). The company posted revenue of $190.01 million in the quarter, versus a consensus estimate of $175.54 million. The company’s revenue for the quarter increased by 441.1% compared to the same quarter last year. In the same quarter a year earlier, the company had earned earnings per share of $3.62.
Several research companies have recently weighed in on BHVN. Mizuho raised its price target on Biohaven Pharmaceutical from $144.00 to $154.00 and gave the company a “buy” rating in a Thursday, March 3 research report. UBS Group raised its target price on Biohaven Pharmaceutical from $150.00 to $160.00 in a Tuesday, January 4 research report. Morgan Stanley lowered its price target on Biohaven Pharmaceutical from $148.00 to $146.00 and set an “equal weight” rating on the stock in a Wednesday, April 6 research report. Finally, HC Wainwright reaffirmed a “buy” rating and published a target price of $160.00 on Biohaven Pharmaceutical shares in a research report on Friday, January 7. Three equity research analysts gave the stock a hold rating and eight gave the stock a buy rating. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $148.27.
In other news, CAD George C. Clark sold 9,375 shares in a trade that took place on Wednesday, January 19. The stock was sold at an average price of $117.01, for a total value of $1,096,968.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, accessible via this hyperlink. Company insiders hold 12.40% of the company’s shares.
A number of institutional investors and hedge funds have recently changed their positions in the company. Russell Investments Group Ltd. increased its position in Biohaven Pharmaceutical shares by 14.5% in the third quarter. Russell Investments Group Ltd. now owns 61,683 shares of the company valued at $8,567,000 after acquiring an additional 7,791 shares in the last quarter. Two Sigma Advisers LP acquired a new position in Biohaven Pharmaceutical during the third quarter worth approximately $5,404,000. Montag A & Associates Inc. acquired a new position in Biohaven Pharmaceutical during the third quarter worth approximately $96,000. Balyasny Asset Management LLC purchased a new stake in shares of Biohaven Pharmaceutical during the third quarter worth approximately $4,785,000. Finally, Teacher Retirement System of Texas increased its stake in Biohaven Pharmaceutical shares by 40.3% during the third quarter. Teacher Retirement System of Texas now owns 9,254 shares of the company worth $1,285,000 after acquiring 2,660 additional shares during the period. Hedge funds and other institutional investors hold 91.73% of the company’s shares.
Shares of Biohaven Pharmaceutical Stock opened at $104.51 on Tuesday. The company has a market capitalization of $7.37 billion, a PE ratio of -7.99 and a beta of 1.06. Biohaven Pharmaceutical has a 12-month low of $65.24 and a 12-month high of $151.51. The stock’s fifty-day moving average is $122.89 and its 200-day moving average is $125.30.
Biohaven Pharmaceutical Company Profile (Get a rating)
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, is developing product candidates targeting neurological and neuropsychiatric diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as the development of Rimegepant for the preventive treatment of migraine; Zavegepant which is in Phase III clinical trials for the acute and preventive treatment of migraine, as well as for respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for Biohaven Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com’s free daily email newsletter.